ArticleJournal for immunotherapy of cancer2023
Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy.
Article in Journal for immunotherapy of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 13 citations in OpenAlex.
- Spatiotemporal CD8Cancer science · 2026Review
- The Steroidal Profile Modulates Adaptive Immune Response and Prognosis in Adrenocortical Carcinoma: Analysis of TCR and BCR Repertoires.Cancer medicine · 2026Article
- Phenotypic, functional, prognostic and predictive significance of B-cell and antibody responses in human melanoma: a scoping review.The British journal of dermatology · 2026Article
- B cell-reactive neoantigens boost antitumor immunity.Science advances · 2025Article
- Latent EBV reactivation drives aberrant B-cell proliferation during ex vivo tumor-infiltrating lymphocyte expansion from EBV-negative rectal cancer tumor tissue.Scientific reports · 2025Article
- The landscape of research on B cell and immunotherapy in solid tumors over the past 20 years.Discover oncology · 2025Article
- Mapping T cell infiltration patterns in glioma tumor tissue.medRxiv : the preprint server for health sciences · 2025Article
- Cyclin E1 overexpression triggers interferon signaling and is associated with antitumor immunity in breast cancer.Journal for immunotherapy of cancer · 2025Article
- Article
- Characterization of TCRβ and IGH Repertoires in the Spleen of Two Chicken Lines with Differential ALV-J Susceptibility Under Normal and Infection Conditions.Animals : an open access journal from MDPI · 2025Article
- The intratumoral landscape of T cell receptor repertoire in esophageal squamous cell carcinoma.Journal of translational medicine · 2024Article
- Exploring the impact of body mass index on tumor biology and cancer development.Journal of cancer research and clinical oncology · 2024Article
- Single-cell aggrephagy-related patterns facilitate tumor microenvironment intercellular communication, influencing osteosarcoma progression and prognosis.Apoptosis : an international journal on programmed cell death · 2024Article
- Identification of prognostic risk model based on plasma cell markers in hepatocellular carcinoma through single-cell sequencing analysis.Frontiers in genetics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundEffective cooperation between B-cells and T-cells within the tumor microenvironment may lead to the regression of established tumors. B-cells and T-cells can recognize tumor antigens with exquisite specificity via their receptor complexes. Nevertheless, whether a diverse intratumoral B-cells and T-cell receptor (BCR, TCR) repertoire affects the tumor immune microenvironment (TIME) and clinical outcomes in patients treated with immunotherapy is unclear.
methodsWe extracted information on BCR and TCR repertoire diversity from large clinical datasets and measured the association between immune receptor diversity features, the TIME, and clinical outcomes of patients treated with anti-PD-1/PD-L1 immunotherapy.
resultsIn multiple tumor types, an increasingly diverse TCR repertoire was strongly associated with a highly activated TIME, while BCR diversity was more associated with antibody responses but not with the overall B-cell infiltration nor with measures related to intratumoral CD8+T cell activity. Neither TCR nor BCR diversity was independent prognostic biomarkers of survival across multiple cancer types. However, both TCR and BCR diversity improved the performance of predictive models combined with established biomarkers of response to immunotherapy.
conclusionOverall, these data indicate a currently unexplored immunological role of intratumoral B-cells associated with BCR diversity and antibody responses but independent of classical anticancer T-cells intratumoral activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.